Association between the androgen levels and erectile function, cognitive functions and hypogonadism symptoms in aging males

Basit Öğe Kaydı
dc.authoridAlan, Cabir/0000-0002-6024-4475
dc.contributor.authorKocoglu, Hasan
dc.contributor.authorAlan, Cabir
dc.contributor.authorSoydan, Hasan
dc.contributor.authorAtes, Ferhat
dc.contributor.authorAdayener, Cuneyt
dc.contributor.authorEren, Ali Erhan
dc.contributor.authorErsay, Ahmet Resit
dc.date.accessioned2025-01-27T20:41:24Z
dc.date.available2025-01-27T20:41:24Z
dc.date.issued2011
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractPurpose: Aging in men is characterized by a moderate decrease in plasma testosterone (T) levels. However, the association between partial androgen deficiency of the aging male and clinical symptoms and the ideal screening test are controversial. In this study, we investigated the association between the androgen levels and erectile function, cognitive functions and hypogonadism symptoms in aging males. Materials and methods: We investigated the association between total (TT), calculated free (FT) and bioavailable (BT) testosterone, and various clinical and laboratory parameters in 103 healthy males, 50-80 years old. Biochemical assessment was done after overnight fasting. Questionnaires were used to test for hypogonadism symptoms, erectile and cognitive functions. Results: TT levels were not correlated with aging in this study. However, FT and BT were found to decrease with age due to rising sex hormone binding globulin. TT levels were strongly correlated with FT and BT levels (respectively p = 0.0001, p = 0.0001). TT, FT and BT were only correlated with cognitive functions (p = 0.012, p = 0.004, p = 0.02 respectively). There was no correlation between TT, FT and BT levels and erectile function and hypogonadism symptoms. Conclusion: T values in our study sample did not correlate with clinical signs and symptoms of hypogonadism. Thus, according to our data, symptoms in the aging male should not be indiscriminately assigned to a decrease in TT, FT or BT levels.
dc.identifier.doi10.3109/13685538.2011.617798
dc.identifier.endpage212
dc.identifier.issn1368-5538
dc.identifier.issn1473-0790
dc.identifier.issue4
dc.identifier.pmid22066788
dc.identifier.scopus2-s2.0-80955143728
dc.identifier.scopusqualityQ2
dc.identifier.startpage207
dc.identifier.urihttps://doi.org/10.3109/13685538.2011.617798
dc.identifier.urihttps://hdl.handle.net/20.500.12428/24133
dc.identifier.volume14
dc.identifier.wosWOS:000296795000001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofAging Male
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectaging male
dc.subjecttestosterone
dc.subjectcognitive function
dc.titleAssociation between the androgen levels and erectile function, cognitive functions and hypogonadism symptoms in aging males
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu